T1	Participants 525 753	premenopausal women who had undergone primary surgery for stage I/II estrogen-receptor-positive and/or progesterone-receptor-positive breast cancer with <10 positive lymph nodes, and were scheduled for standard goserelin therapy
T2	Participants 759 772	1803 patients
T3	Participants 182 240	Austrian Breast and Colorectal Cancer Study Group Trial 12
#1	AnnotatorNotes T3	Participants were those in this trial (currently being followed-up).
